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Induction docetaxel and cisplatin followed of bi-weekly docetaxel 
with concurrent thoracic radiotherapy for stage III non-small cell 
lung cancer (NSCLC). A phase II study conducted by the Galician 
Lung Cancer Group (GLCG).
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Background: The most satisfactory treatment for patients with locally 
advanced NSCLC is combination chemotherapy-radiotherapy (CT-RT). 
The optimal treatment modalities remain to be determined.
Methods: 60 patients (pts) with inoperable locally advanced NSCLC, 
stage IIIAN2/IIIB (no pleural T4), were included in a phase II study 
with induction chemotherapy consisting of three cycles of Docetaxel 
75 mg/m2 on D1 and Cisplatin 40 mg/m2 D1-2 every 3 weeks and, if 
no surgery, then received concurrent CT-RT with Docetaxel 30 mg/m2 
every 2 weeks for four courses, during thoracic conformal radiotherapy 
(60-66 Gys, 180 cGy/day). The primary objective: overall survival; 
secondary: progression free survival, response rate (RR) and toxicity. 
Median follow-up: 9.1 mo.
Results: The pts characteristics were: mean age 62.9 yrs (43-74); male/
female: 56/4; ECOG 0/1 in 17/43 pts; stage IIIAN2: 17 pts (28.3%) and 
stage IIIB 43 pts (71.7%). 56 pts were evaluables for response and 58 
pts for toxicity. Induction chemotherapy response: 1 CR and 34 PR (RR 
62.5%; CI95%:50-75), 16 SD (28.6%) and 5 PD (8.9%). 6 pts went to 
surgery: 3 pPR, 1 pSD, 1 pPD and 1 unresectable. 34 pts completed 
concurrent CT-RT treatment with 6 CR, 21 PR, 4 SD and 3 PD (RR 
79.3%; CI95%:66-93). The median time to progression was 13 mo and 
median overall survival was 14 mo. The progression-free survival and 
overall survival at 1 year was 52% and 62% respectively. A total of 
163 cycles of induction chemotherapy were administered (2.8 per pts), 
with the main toxicity (NCI-CTC) per pts Grade (g) 1-2/3-4 (%) was 
as follows: neutropenia 20.6/24.1; anemia 44.8/1.7; nausea/vomiting 
39.6/1.7; fatigue 34.5/1.7; diarrhea 22.4/0; allergy 5.2/1.7; one toxic 
death were scored. The main toxicities (RTOG) in concurrent CT-RT 
were: g1-2 neutropenia/anemia 30.7/38.4 5% of pts; g1-2/3 esophagitis 
in 51.2/2.5% and g1-2/3 pneumonitis in 20.5/2.5 % of pts.
Conclusions: Docetaxel and Cisplatin induction chemotherapy fol-
lowed by bi-weekly docetaxel with concurrent thoracic radiotherapy 
is a feasible treatment option, showing good clinical activity and toler-
ability for locally advanced NSCLC.
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Is 2D versus 3D planning detrimental for local control and survival 
in preoeperative radiochemotherapy in NSCLC?
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Background: We carried out a phase II trial to evaluate a regimen of 
polychemotherapy delivered concurrently with accelerated modiﬁed 
hyperfracctionated radiotherapy (AMHR) in NSCLC stage III patients. 
A subanalysis was made of the impact of planning method (2D versus 
3D) on local control and overall survival.
Methods: Thirty eight patients (pts) received neoadjuvant therapy 
consisting of AMHR 40.2 Gy over 3 weeks (1,8 +0,88 Gy, by concomi-
tant boost), concurrent with the second cycle of chemotherapy using 
cisplatin 80 ml/m2 on day 1, ifosfamide 1.5 gr/m2 on day 1 and VP-16 
100 mg/m2 for 3 days. 
Results: From October 1997 to October 2002, 38 pts were treated. 
The most frequent cell type was squamous cell carcinoma, 20 (54%), 
and adenocarcinoma 11, (30%). From 1997 to June 1999, 17 pts were 
prepared with 2D. After this date 21 pts were done with 3D. Clinical 
response to CRT at restaging was observed in 30 pts (79%). One pt 
(3%) had complete response, 16 pts (42%) partial response, 13 (34%) 
stable disease and 4 pts (8%) developed progression. Surgery included 
pneumonectomy (n=14), bilobectomy (n=1) and lobectomy (n=14) and 
exploratory thoracotomy (n=1). Pathologic examination of the resected 
tissue demonstrated no residual viable tumor, (pathologic CR) in 13 / 
28 completely resected pts (45%). Clinical response of pts with pCR 
when evaluated before surgery was partial in 8, stable disease in 4 and 
complete response in one. Overall 20 (69%) pts had sterilization of 
mediastinal lymph nodes and downstaging .There was 1 surgically-re-
lated death. Maximum toxicity was: esophagitis grade II in 8 pts (22%) 
and III in 1 pt (3%), neutropenia grade III -IV in 24%, thrombocyto-
penia grade III-IV in 13% and anemia grade III-IV in 10.5%. Twelve 
pts (32%) required hospitalisation due to toxicity. Stratiﬁed by type of 
planning disease free survival differed with more local control in the 
2D arm ( 16 months for 2D versus 11.91months with 3D) but without 
statistical signiﬁcance. Overall survival was also equivalent.
Median survival for the whole series was 22 months with survival at 5 
years being 21.38 %. Median and 5 - year survival for patients who did 
or did not undergo surgery were 26.5 months, 35% and 8 months and 
0%, respectively .
Conclusions: In this neoadjuvant radiochemotherapy treatment the 
type of planning ( 2D versus 3D) is not signiﬁcantly detrimental on 
local control or overall survival although a trend to lesser local control 
has been detected in pts prepared for 3D. This trend may be due to 
the learning curve and a lack of planning norms such as published by 
Senan et al in 2004.
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Carboplatin and Gemcitabine as adjuvant therapy in completely 
resected stage I-IIIA non small cell lung cancer patients
Charpidou, Andriani G.1 Katirtzoglou, Evgenia2 Zalonis, Antonis2 
Pantazopoulos, Kosmas2 Tzanou, Iﬁgenia2 Katirtzoglou, Nikolaos2 
Georgatou, Niki3 Gaga, Mina4 Syrigos, Kostas N.2 
1 Oncology Unit, 3rd Dpt of Medicine, Athens Med School, Athens, 
Greece 2 Oncology Unit, 3rd Dpt of Internal Medicine, Athens Medical 
School, Athens, Greece 3 5th Dpt of Chest Diseases, Sotiria General 
Hospital, Athens, Greece 4 7th Dpt of Chest Diseases, Sotiria General 
Hospital, Athens, Greece 
Purpose: To evaluate the efﬁcacy, toxicity and compliance associated 
with adjuvant Carboplatin and Gemcitabine (CBDCA - GEM) admin-
istration in completely resected patients with stage I - IIIA non-small 
lung cancer (NSCLC) 
